Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
| Заболевание | Glioblastoma |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | University of Pennsylvania |
| Статус | Идёт, набор закрыт |
| Участники | 39 участн. |
| Вмешательство | INCMGA00012, INCAGN01876, SRS, Brain surgery |
| Дата начала | 23.06.2020 |
| Дата завершения | 8.09.2022 |
| Публикация результатов | 15.09.2023 |
Кратко
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
Objective Radiographic Response (ORR)
| GITR + PD1, SRS (Cohort A) | 0 % of participants with response |
|---|
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen